Healthcare Services

Epidermolysis bullosa market expected to reach $4.79B by 2030

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Epidermolysis Bullosa Market Between 2026 And 2030?

The epidermolysis bullosa market has seen substantial growth in recent years. Its value is expected to rise from $3.43 billion in 2025 to $3.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. The expansion observed historically can be attributed to genetic disorder identification, limited treatment options, the use of wound care products, the increasing prevalence of rare disease advocacy, and hospital-based supportive care.

The market for epidermolysis bullosa is projected to experience robust expansion in the coming years. This market is predicted to reach $4.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. Several factors contribute to this anticipated growth, including the expansion of gene therapy pipelines, incentives for orphan drugs, the increasing adoption of personalized medicine, a rise in homecare services, and earlier genetic diagnosis. Key trends expected during this period involve a heightened focus on gene and cell therapies, a growing need for sophisticated wound care, an increase in rare disease research initiatives, the broadening of home-based supportive care, and a strong emphasis on multidisciplinary patient management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/epidermolysis-bullosa-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Epidermolysis Bullosa Market?

Elevated research and development activities are projected to propel the future growth of the epidermolysis bullosa market. These activities denote systematic efforts dedicated to innovating, improving, or developing new products, processes, or technologies. The expansion of research and development activities stems from a surging demand for innovative treatments, advanced therapies, and precision medicine aimed at addressing complex diseases. These R&D endeavors drive the discovery of novel therapies, superior wound care solutions, and potential gene and cell-based treatments, consequently enhancing the diagnosis, management, and quality of life for epidermolysis bullosa patients. For instance, in April 2025, as per the Office for National Statistics, a UK-based executive office, the UK government’s net expenditure on research and development (R&D) climbed to $21.6 billion (£17.4 billion) in 2023 from $20.0 billion (£16.1 billion) in 2022, representing an 8.2% increase. Thus, the escalating research and development activities are driving the growth of the epidermolysis bullosa market.

Which Segment Categories Are Included In The Epidermolysis Bullosa Market Segment Analysis?

The epidermolysis bullosa market covered in this report is segmented –

1) By Product Type: Antibiotic, Analgesics, Other Product Types

2) By Mode Of Administration: Injectables, Oral, Other Modes Of Administrations

3) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antibiotic: Topical Antibiotics, Oral Antibiotics, Injectable Antibiotics

2) By Analgesics: NSAIDs, Opioids, Topical Pain Relievers

3) By Other Product Types: Wound Dressings, Immunotherapies, Gene Therapies

Which Trends Are Shaping The Epidermolysis Bullosa Market?

Leading companies in the epidermolysis bullosa market are concentrating on advanced treatments, such as redosable gene therapy, to enhance long-term effectiveness and improve patient outcomes. Redosable gene therapy is a treatment that can be administered multiple times to sustain or augment therapeutic effects, distinguishing it from conventional one-time gene therapies. For example, in May 2023, Krystal Biotech Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved VYJUVEK, a redosable gene therapy, for treating patients aged six months and older with dystrophic epidermolysis bullosa (DEB). This innovative therapy delivers a functional copy of the COL7A1 gene, targeting the fundamental cause of DEB by addressing the underlying genetic defect. Designed for topical application, VYJUVEK presents a more convenient and less invasive alternative to traditional systemic treatments, thereby enhancing patient care and improving treatment accessibility.

Who Are The Active Companies Shaping The Epidermolysis Bullosa Market?

Major companies operating in the epidermolysis bullosa market are LEO Pharma A/S, BridgeBio Pharma Inc., Amicus Therapeutics Inc., Amryt Pharma plc, Krystal Biotech Inc., Castle Creek Biosciences Inc., RHEACELL GmbH & Co. KG, BioMendics LLC, ProQR Therapeutics N.V., Holostem Terapie Avanzate Srl, TWi Biotechnology Inc., Abeona Therapeutics Inc., Phoenix Tissue Repair Inc., Phoenicis Therapeutics, Anterogen Co Ltd, Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, InMed Pharmaceuticals Inc., Aegle Therapeutics Corp., Wings Therapeutics Inc., RegeneRx Biopharmaceuticals Inc., Ishin Pharma, Menlo Therapeutics Inc., JCR Pharmaceuticals, Fibrocell Science Inc., Smith & Nephew plc, ConvaTec Group plc.

Get The Full Epidermolysis Bullosa Market Report:

https://www.thebusinessresearchcompany.com/report/epidermolysis-bullosa-global-market-report

Which Region Is The Top Contributor To The Epidermolysis Bullosa Market By Share?

North America was the largest region in the epidermolysis bullosa market in 2025. The regions covered in the epidermolysis bullosa market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Epidermolysis Bullosa Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/epidermolysis-bullosa-global-market-report

Browse Through More Reports Similar to the Global Epidermolysis Bullosa Market 2026, By The Business Research Company

Skin And Hide Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-and-hide-global-market-report

Scar Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/scar-treatment-global-market-report

Hypertrophic And Keloid Scar Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypertrophic-and-keloid-scar-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795